Biomea Fusion, Inc.BMEAEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel covalent small molecule therapies for genetically defined cancers and other serious life-threatening diseases. Its lead pipeline candidates target key oncogenic drivers, addressing high unmet medical needs across global patient populations.
Revenue
$165.0M
Gross Profit
N/A
Operating Profit
$-23.5M
Net Profit
$-22.9M
Gross Margin
N/A
Operating Margin
-14.2%
Net Margin
-13.9%
YoY Growth
N/A
EPS
$-0.78
Biomea Fusion, Inc. Q3 FY2022 Financial Summary
Biomea Fusion, Inc. reported revenue of $165.0M for Q3 FY2022, with a net profit of $-22.9M (down 81.6% YoY) (-13.9% margin).
Key Financial Metrics
| Total Revenue | $165.0M |
|---|---|
| Net Profit | $-22.9M |
| Gross Margin | N/A |
| Operating Margin | -14.2% |
| Report Period | Q3 FY2022 |
Biomea Fusion, Inc. Quarterly Revenue & Net Profit History
Biomea Fusion, Inc. results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $-3.5M | -556.7% | $4.6M | -130.8% |
| Q3 FY2022 | $165.0M | — | $-22.9M | -13.9% |
| Q2 FY2022 | $0 | — | $-17.3M | N/A |
| Q1 FY2022 | $1.1B | +0.0% | $-16.4M | -1.5% |
Income Statement
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2025 | |
|---|---|---|---|---|
| Revenue | $1.07B | $0 | $165.0M | $-3.5M |
| YoY Growth | 0.0% | N/A | N/A | -556.7% |
Balance Sheet
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2025 | |
|---|---|---|---|---|
| Assets | $174.9M | $161.7M | $145.1M | $58.6M |
| Liabilities | $10.1M | $11.3M | $14.4M | $29.0M |
| Equity | $164.8M | $150.4M | $130.6M | $29.6M |
Cash Flow
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2025 | |
|---|---|---|---|---|
| Operating CF | $-10.0M | $-15.4M | $-16.8M | $-13.9M |